A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Phase 3
Completed
NCT02754882
| Condition | Lung Cancer, Non-small Cell Lung Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Samsung Bioepis Co., Ltd. |
|---|
| Status | Completed |
|---|
| Enrollment | 763 participants |
|---|
| Interventions | Bevacizumab, SB8, Carboplatin, Paclitaxel |
|---|
| Start date | Jul 5, 2016 |
|---|
| Completion date | Jan 24, 2018 |
|---|
| Results posted | Dec 16, 2024 |
|---|
Summary
This study is designed to establish biosimilarity of SB8, a proposed biosimilar product of bevacizumab, to EU-sourced bevacizumab, in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).
Percentage of Participants With Best Overall Response (Best Overall Response Rate[ORR]) by 24 Weeks
24 weeks from randomisation · percentage of participants
| Bevacizumab (Avastin) | 42.8 percentage of participants |
|---|
| SB8 (A Proposed Bevacizumab Biosimilar) | 47.6 percentage of participants |
|---|
| Risk Ratio (RR) | 1.11 (95% CI 0.975–1.269) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.